Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Allergy Thera. (AGY) Share Price

Price 5.80p on 18-04-2025 at 04:45:06
Change 0.00p 0%
Buy 6.00p
Sell 5.50p
Buy / Sell AGY Shares
Last Trade: Buy 30,000.00 at 5.80p
Day's Volume: 0
Last Close: 5.80p
Open: 0.00p
ISIN: GB00B02LCQ05
Day's Range 0.00p - 0.00p
52wk Range: 2.74p - 7.70p
Market Capitalisation: £276m
VWAP: 0.00p
Shares in Issue: 4,766m

Allergy Thera. (AGY) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 30,000 5.80p Suspected BUY Trade
16:35:18 - 17-Apr-25
Sell* 20,000 5.70p Uncrossing Trade
11:00:29 - 17-Apr-25
Sell* 42,000 5.505p Ordinary
08:25:30 - 17-Apr-25
Sell* 2,000 5.505p Ordinary
08:19:10 - 17-Apr-25
Sell* 65,000 5.70p Uncrossing Trade
16:35:08 - 16-Apr-25
Sell* 20,000 5.70p Uncrossing Trade
14:00:01 - 16-Apr-25
Buy* 15,000 5.80p Suspected BUY Trade
11:00:21 - 16-Apr-25
Sell* 21,187 5.505p Ordinary
10:34:54 - 16-Apr-25
Buy* 20,000 5.80p Suspected BUY Trade
09:00:10 - 16-Apr-25
Buy* 166 6.00p SI Trade
08:00:40 - 16-Apr-25
See more Allergy Thera. trades

Allergy Thera. (AGY) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Apr 2025 (Fri) 5.80 5.80 5.80 5.80 0
17th Apr 2025 (Thu) 5.70 5.80 5.70 5.80 277,174
16th Apr 2025 (Wed) 5.90 5.90 5.70 5.70 161,353
15th Apr 2025 (Tue) 5.80 6.00 5.70 5.70 136,831
14th Apr 2025 (Mon) 5.25 5.75 5.60 5.70 319,956
11th Apr 2025 (Fri) 5.25 5.70 5.25 5.25 88,692
10th Apr 2025 (Thu) 5.85 5.90 5.50 5.50 270,863
9th Apr 2025 (Wed) 5.40 5.90 5.25 5.75 102,090
8th Apr 2025 (Tue) 6.00 6.00 5.25 5.70 714,642
7th Apr 2025 (Mon) 6.45 6.45 6.15 6.15 779,757
4th Apr 2025 (Fri) 6.40 6.45 6.00 6.45 251,734
3rd Apr 2025 (Thu) 6.45 6.45 6.00 6.25 479,832
2nd Apr 2025 (Wed) 6.45 6.45 5.85 6.40 327,467
1st Apr 2025 (Tue) 6.00 6.45 6.00 6.45 119,259
31st Mar 2025 (Mon) 6.50 6.50 6.30 6.30 358,971
28th Mar 2025 (Fri) 6.60 6.60 6.25 6.48 118,962
27th Mar 2025 (Thu) 6.60 6.60 6.50 6.60 538,045
26th Mar 2025 (Wed) 6.60 6.90 6.50 6.50 98,317
25th Mar 2025 (Tue) 6.80 6.80 6.20 6.50 189,935
24th Mar 2025 (Mon) 6.80 6.80 6.50 6.80 361,656
21st Mar 2025 (Fri) 6.76 7.00 6.50 6.80 144,932
20th Mar 2025 (Thu) 6.50 6.80 6.50 6.70 74,726
19th Mar 2025 (Wed) 7.00 7.00 6.60 6.60 614,621
See more Allergy Thera. price history

Allergy Thera. (AGY) Share News

Allergy Therapeutics half-year loss narrows on lower expenses

31st Mar 2025 12:24

(Alliance News) - Allergy Therapeutics PLC on Monday said talks are underway regarding further financing as it said reduced costs helped trim its half-year loss. Read More

Allergy Therapeutics peanut allergy vaccine trial enters final phase

27th Mar 2025 18:27

(Alliance News) - Allergy Therapeutics PLC on Thursday said its peanut allergy vaccine trial has entered the final treatment phase. Read More

IN BRIEF: Allergy Therapeutics expects annual sales to rise on-year

28th Jan 2025 21:19

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Expects revenue to rise by 1.1%, or by 4% at constant currency, to GBP34.0 million in the six months ended December from GBP33.6 million a year ago. Sales are expected to continue to grow in the second half of the financial year. Overall, expects sales for the full year ending June 30 to exceed sales in the corresponding period ended June 2024. Reports cash position of GBP21.7 million at the end of December, rising from GBP12.9 million a year ago, following receipt of new GBP20 million five-year term loan. Chief Executive Manuel Llobet says: "We enter 2025 building strong momentum across all aspects of our business. Our return to first-half growth and strengthened position, having secured the Hayfin facility in late 2024, give us the confidence and financial stability to further our ambitious strategy." Read More

UK shareholder meetings calendar - next 7 days

9th Dec 2024 11:30

Read More

IN BRIEF: Allergy Therapeutics treats first patient in allergy trial

27th Nov 2024 16:52

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Treats its first patient in the third phase of its paediatric trial of Grass Mata MPL. The trial aims to evaluate the long-term efficacy and safety of the drug in treating children with grass pollen allergies. The drug was trialled in adults last year, and showed a "highly statistically significant reduction in the combined symptom and medication score". Grass Mata MPL addresses the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, and works to modify the body's allergic response in as few as six injections ahead of the allergy season. Read More

See more Allergy Thera. news
FTSE 100 Latest
Value8,275.66
Change0.00

Login to your account

Forgot Password?

Not Registered